紫杉醇联合卡铂治疗晚期非小细胞肺癌

Paclitaxel combined with carboplatin in the treatment of advanced non-small cell lung cancer

目的 评价紫杉醇加卡铂联合化疗对晚期非小细胞肺癌 (NSCLC)病人的疗效及毒副作用。方法 紫杉醇每次剂量175 /m2 ,3h静脉滴注 ,于第 1天给药。在紫杉醇化疗前给予地塞米松、苯海拉明和西咪替丁预防过敏反应。卡铂每次剂量30 0mg/m2 ,1h静脉滴注 ,于第 1天给药。化疗周期每 3周重复。结果 共 86例病人接受 2～ 7个疗程的化疗。总缓解率为4 9 % ,5例 (6 % )完全缓解 ,37例 (43% )部分缓解 ,35例 (41% )肿瘤稳定 ,9例 (10 % )肿瘤发展。中位缓解期 7个月 ,全组中位生存期 11个月。本方案化疗所致的毒性反应主要为骨髓抑制 肌肉关节痛 手足感觉异常和脱发 ,通常为轻度反应 (1度或2度反应 )。结论 紫杉醇加卡铂是治疗晚期NSCLC有效的联合化疗方案 ,其毒性反应容易耐受 ,该方案值得进一步临床研究。

Objective To evaluate the efficacy and toxicity of paclitaxel combined with carboplatin chemotherapy in patients with advanced non-small cell lung cancer(NSCLC).Methods,Paclitaxel was administered by 3 hour introvenous infusion at a dose of 175 nag/m2 on day 1.Dexamethasone,diphenhydramine and cimetidine were given before paclitaxd to prevent allergic reactions.Carboplatin Was given byl hourintravenousinfusion at a dose of 300mg/m2on dayl.Chemotherapy cycleswere repeated every3 weeks.Results A total of 86 patients received 2 to 7 cycles of chemotherapy.The overall response rate Was 49%,with 5(6%)complete responses and 37(43%)partial responses.The disease was stable in 35 patients(41%)and was progressive in 9 patients(10%).The median duration of response was 7 months and the median overall survival time Was 11 months.The major toxic reactions associated with this chemotherapy regimen were myelosuppression,myalgias/arthralgia,peripheral neuropathy,and alopecia;but they were generally mild (grade 1 or 2).Conclusion The paclitaxel-carboplatin chemotherapy regimen is an effective method with tolerable toxcity in advanced NSCLC and deserves further dinical investigation.